Hematology-American Society of Hematology Education Program

Article	Citations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	77
Your chemo is no good here: management of high-risk MCL	76
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	68
Bispecific antibody therapies	50
Labor and delivery: DIC, HELLP, preeclampsia	47
Anticoagulation at the end of life: whether, when, and how to treat	40
Inpatient recognition and management of HLH	39
Neurological manifestations of MGUS	38
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	36
Mastocytosis demystified	35
On the horizon: upcoming new agents for the management of ITP	35
Diagnosis and therapeutic decision-making for the neutropenic patient	33
Recognizing, defining, and managing CAR-T hematologic toxicities	32
Has PD-1 blockade changed the standard of care for cHL?	31
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	31
Divergent paths: management of early relapsed follicular lymphoma	26
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	26
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	26
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	26
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	26
Troubleshooting heparin resistance	25
Selecting initial therapy in CLL	25
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	24
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	24

Optimizing outcomes in secondary AML	23
New approaches to tackle cytopenic myelofibrosis	23
BV and beyond: how to incorporate novel agents into PTCL management	23
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	23
How to assess hemostasis in patients with severe liver disease	23
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	21
How to manage hemostasis in patients with liver disease during interventions	21
MGCS: where do we stand today?	21
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	21
How to recognize and manage COVID-19-associated coagulopathy	21
Fitness and frailty in myeloma	21
Consumptive coagulopathy in the ICU	20
Management of TKI-resistant chronic phase CML	20
Running interferon interference in treating PV/ET: meeting unmet needs	20
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	20
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	20
How to diagnose and manage antiphospholipid syndrome	19
Hemophilia gene therapy: ushering in a new treatment paradigm?	19
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	19
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	19
Demystifying autoimmune HIT: what it is, when to test, and how to treat	18
Management of marginal zone lymphomas	18
Hematology 2022—what is complete HLA match in 2022?	18
Managing therapy-associated neurotoxicity in children with ALL	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
Special considerations in GI bleeding in VWD patients	18
Atypical CML: diagnosis and treatment	18
Approaches to management of HIT in complex scenarios, including cardiac surgery	17
What to use to treat AML: the role of emerging therapies	17
How to manage bleeding disorders in aging patients needing surgery	17
Management of limited-stage Hodgkin lymphoma	17
Thrombosis questions from the inpatient wards	17
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	17
Infectious complications and vaccines	16
Lower risk but high risk	16
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	16
CNS prophylaxis in aggressive B-cell lymphoma	15
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	15
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	14
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	14
Alloimmunization and hyperhemolysis in sickle cell disease	14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
Thrombocytopenia in pregnancy	14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	14
Organ function indications and potential improvements following curative therapy for sickle cell disease	14
When does a PNH clone have clinical significance?	14
Treatment of VTE in the thrombocytopenic cancer patient	14
Transplant in AML with measurable residual disease: proceed or defer?	14

The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Ph− ALL: immunotherapy in upfront treatment	13
Cytoreduction for ET and PV: who, what, when, and how?	13
What makes a pediatric or young adult patient an appropriate transplant candidate?	13
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	13
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	13
Pegylated interferon: the who, why, and how	13
Next-generation therapy for lower-risk MDS	13
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	12
Managing side effects: guidance for use of immunotherapies in multiple myeloma	12
Whom should we treat with novel agents? Specific indications for specific and challenging populations	12
Frontline treatment in CLL: the case for time-limited treatment	12
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	12
Clinical manifestations of telomere biology disorders in adults	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
What else do I need to worry about when treating graft-versus-host disease?	12
Should we use bisphosphonates to treat bone complications in sickle cell disease?	12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	12
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	12
Novel therapies upon failure of HMA plus venetoclax	12
The role of stem cell transplant (auto and allo) in PTCL and CTCL	12
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	11
Warm autoimmune hemolytic anemia and the best treatment strategies	11
Treatment of older adult or frail patients with multiple myeloma	11
von Willebrand disease and heavy menstrual bleeding: when and how to test	11
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	11
IV iron formulations and use in adults	11
In 2022, which is preferred: haploidentical or cord transplant?	11
Diamond-Blackfan anemia	11
Immunology 101: fundamental immunology for the practicing hematologist	11
Sequencing bispecific antibodies and CAR T cells for FL	11
Approach to the patient with suspected hypereosinophilic syndrome	11
Barriers to accessing cellular therapy for patients receiving care in community practices	11
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	11
Porphyria cutanea tarda: a unique iron-related disorder	11
Are transplant indications changing for myelofibrosis?	10
When should we use it? The role of brentuximab vedotin in 2024	10
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	10
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	10
The approach of HMA plus VEN with or without BMT for all patients with AML	10
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	10
Long-term prophylaxis: what are our options and how to define success?	10
Psychosocial and financial issues after hematopoietic cell transplantation	10
Sequencing therapy in relapsed DLBCL	10
Clonal hematopoiesis in frequent whole blood donors	10
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	10
Diagnosis and clinical management of enzymopathies	10
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	9
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	9
Management of Fanconi anemia beyond childhood	9
Risk-stratification in frontline CLL therapy: standard of care	9
Heparin-induced thrombocytopenia and cardiovascular surgery	9
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	9
The intersection of sickle cell disease, stigma, and pain in Africa	9
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	9
Amyloid consults do not have to be vexing	9
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	9
Multiple myeloma: a paradigm for blending community and academic care	9
The first relapse in multiple myeloma: how to pick the next best thing	9
Novel platelet products including cold-stored platelets	9
New definitions for antiphospholipid syndrome: ready for clinical use?	9
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	9
Using disease-modifying therapies in sickle cell disease	9
Newborn screening initiatives for sickle cell disease in Africa	8
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	8
Clonal evolution in inherited marrow failure syndromes predicts disease progression	8
Acute lymphoblastic leukemia in young adults: which up-front treatment?	8
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	8
Cryptogenic oozers and bruisers	8
Diagnosis and clinical management of red cell membrane disorders	8
When to consider inherited marrow failure syndromes in adults	8
Renal manifestations of MGUS	8
Novel clinical care models for patients with sickle cell disease	8
Transplantation in CML in the TKI era: who, when, and how?	8
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	8
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	8
COVID-19 and thrombosis: searching for evidence	8
New investigational combinations for higher-risk MDS	8
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.	8

Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	8
Maintenance strategies for relapse prevention and treatment	8
Double-hit lymphoma: optimizing therapy	8
Current use of bispecific antibodies to treat multiple myeloma	7
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	7
Potential and emerging therapeutics for HHT	7
Management of hemolytic transfusion reactions	7
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	7
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.	7
How immunodeficiency can lead to malignancy	7
Challenges to successful outcomes in AYAs with ALL and potential solutions	7
Sickle cell disease in India: the journey and hope for the future	7
Epidemiology and treatment of priapism in sickle cell disease	7
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	7
How to manage ITP with life-threatening bleeding	7
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	7
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	7
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	7
Ph+ ALL in 2022: is there an optimal approach?	7
Unexplained arterial thrombosis: approach to diagnosis and treatment	7
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.	7
Ph+ ALL: new approaches for upfront therapy	7
Late complications and long-term care of adult CAR T-cell patients	6
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	6
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	6
Dual-targeted regimens for the frontline treatment of CLL	6
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	6
Cellular therapy for multiple myeloma: what's now and what's next	6
Optimal approach to T-cell ALL	6
AL amyloidosis: untangling new therapies	6
High-risk multiple myeloma: how to treat at diagnosis and relapse?	6
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	6
Acute GVHD: think before you treat	6
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	6
Inflamed—HLH, MAS, or something else?	5
The 5 most frequently asked questions about factor Xa inhibitors	5
Advances in the management of α-thalassemia major: reasons to be optimistic	5
Incorporating gonadal health counseling into pediatric care of sickle cell patients	5
Current use of CAR T cells to treat multiple myeloma	5
Allogeneic transplantation for advanced acute leukemia	5
Passive immune therapies: another tool against COVID-19	5
Identifying and treating iron deficiency anemia in pregnancy	5
Novel approaches to acute graft-versus-host disease prevention	5
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond	5
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	5
When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow	5
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	5
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	5
Approaches to optimize outcomes in transplant recipients	5
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	5
Givosiran: a targeted treatment for acute intermittent porphyria	5
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	5
Modified T cells as therapeutic agents	5
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	5
Mutational screening to improve the transplantation decision-making process in MDS	5
The burden of myeloma: novel approaches to disease assessment	5
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	5
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	5
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	5
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	5
Platelet components and bacterial contamination: hospital perspective 2022	5
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	5
Perioperative consultative hematology: can you clear my patient for a procedure?	5